Rhythm Pharmaceuticals, Inc. (RYTM): R&D Expense
$167.34M
Year ended 2025-12-31
$173.21M
Trailing 12 months to 2026-06-30
+15.5%
3-year compound annual growth
+13.1%
5-year compound annual growth
+37.1%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $167.34M | -29.7% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $237.96M | +76.3% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $134.95M | +24.2% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $108.63M | +4.3% | 2025-02-28, From 2022-01-01 |
| 2021-12-31 | $104.13M | +15.1% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $90.45M | -17.4% | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | $109.45M | +117.4% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $50.34M | +119.9% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $22.89M | +16.8% | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | $19.59M | +174.1% | 2019-03-08, From 2016-01-01 |
| 2015-12-31 | $7.15M | n/a | 2018-03-12, From 2015-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $167.34M | -29.7% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $17.40M | -9.5% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $137.92M | +54.7% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $1.00M | -28.6% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $17.04M | -3.8% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $32.78M | -3.8% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $258.78M | +7.1% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $19.81M | -5.1% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $109.27M | +46.8% |
Compare RYTM, MRVI, STOK, LFVN side by side · Screen every company in Pharmaceutical Preparations ↗